Durvalumab (MEDI4736) is a fully human monoclonal antibody targeting PD-L1 [40] which improved the OS of patients with advanced NSCLC [41], advanced urothelial bladder cancer [42], HNSCC progressed on platinum-based chemotherapy [43]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.